Identification and Selection of "Privileged Fragments" Suitable for Primary Screening. - Eleonora Gianti; Luca Sartori (J. Chem. Inf. Model., 2008)

Modeling Androgen Receptor Flexibility: A Binding Mode Hypothesis of CYP17 Inhibitors/Antiandrogens for Prostate Cancer Therapy. - Eleonora Gianti; Randy J. Zauhar (J. Chem. Inf. Model., 2012)

Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery. - Randy J. Zauhar; Eleonora Gianti; William J. Welsh (J. Comput. Aided Mol. Des., 2013)

An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures". - Eleonora Gianti; Randy J. Zauhar (J. Comput. Aided Mol. Des., 2015)

Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design. - Eleonora Gianti; Troy E. Messick; Paul M. Lieberman; Randy J. Zauhar (J. Comput. Aided Mol. Des., 2016)